The two equations most used to calculate eGFRcr in the United States, the Modification of Diet in Renal Disease (MDRD) Study, and the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equations, include a race coefficient. As race is a subjective, social construct, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force in 2020 to reassess the inclusion of race in diagnosing kidney diseases in the United States. The NKF-ASN Task Force employed a holistic approach incorporating input from the medical community and patients to identify an approach that balanced social justice with scientific rigor.
The final NKF-ASN Task Force report recommends:
- The use of the CKD-EPI 2021 eGFR creatinine equation for calculating eGFRcr in adults.2,3 This new equation is recommended because a race coefficient is not included in its computation and reporting. The CKD-EPI 2021 eGFR creatinine equation included diversity in its development and does not disproportionately affect any one group.3
- National efforts are also underway to facilitate increased, routine, and timely use of cystatin C (CPT 82610), especially to further evaluate eGFRcr in adults who are at risk for or have chronic kidney disease, or in individuals with abnormally high or low muscle mass. The CKD-EPI 2021 eGFR using creatinine and cystatin C (eGFRcr-cys) is more accurate, more closely approximates measured GFR and supports better clinical decisions than either marker alone.2,3
The nation’s laboratories are working to employ a consistent, standardized approach for estimating GFR to improve testing for kidney diseases. Together, the laboratory organizations below endorse the national implementation of the CKD-EPI 2021 creatinine and creatinine-cystatin C equations for the estimation of glomerular filtration rate.
Laboratory Organizations
|
Academy of Clinical Laboratory Physicians |
Clinical Laboratory Management |
|
American Association of Clinical Chemistry |
College of American Pathologists (CAP) |
|
American Society for Clinical Pathology |
National Independent Laboratory |
|
Association of Pathology Chairs (APC) |
Society of American Federated Medical |
References:
- Choosing Wisely, an initiative of the ABIM Foundation. American Society of Clinical Pathology. Recommendation for Chronic Kidney Disease
Testing. 2018. at bit.ly/2SFSz3u - Delgado C, Baweja M, Crews DC, et al. A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on
Reassessing the Inclusion of Race in Diagnosing Kidney Disease. American Journal of Kidney Diseases. DOI: 10.1053/j.ajkd.2021.08.003. - Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. New England Journal of
Medicine 2021. DOI: 10.1056/NEJMoa2102953.
About Kidney Disease
In the United States, 37 million adults are estimated to have kidney disease, also known as chronic kidney disease (CKD)—and approximately 90 percent don’t know they have it. 1 in 3 adults in the U.S. are at risk for kidney disease. Risk factors for kidney disease include: diabetes, high blood pressure, heart disease, obesity, and family history. People of Black/African American, Hispanic/Latino, American Indian/Alaska Native, Asian American, or Native Hawaiian/Other Pacific Islander descent are at increased risk for developing the disease. Black/African American people are more than 3 times as likely as White people to have kidney failure. Hispanics/Latinos are 1.3 times more likely than non-Hispanics to have kidney failure.
About the National Kidney Foundation
The National Kidney Foundation (NKF) is the largest, most comprehensive, and longstanding patient-centric organization dedicated to the awareness, prevention, and treatment of kidney disease in the U.S. For more information about NKF, visit www.kidney.org.
Facebook.com
www.kidney.org
twitter.com/nkf
SOURCE National Kidney Foundation
